Home » FDA: Multaq Not Safe for Use in Subgroup of AF Patients
FDA: Multaq Not Safe for Use in Subgroup of AF Patients
The FDA is requiring a boxed warning for Sanofi-Aventis’ atrial fibrillation (AF) treatment Multaq in patients with permanent AF after a safety review showed a higher risk of cardiovascular (CV) death.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May